Creative Medical enhances diabetes treatment with AI tech

PHOENIX - Creative Medical (TASE:PMCN) Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology firm, has announced a strategic collaboration with Greenstone Biosciences Inc. to utilize Artificial Intelligence (AI) in advancing its stem cell platform for diabetes treatment. This partnership builds on Creative Medical’s existing work with hypoimmune induced pluripotent stem cell (iPSC) technology, notably its iPSC-derived pancreatic islet cells currently in clinical trials.

The alliance is set to employ AI in drug discovery to find small molecules that can improve insulin secretion from these cells. Additionally, the collaboration will focus on multi-gene editing to enhance the next generation of hypoimmune iPSC lines. These improvements aim to optimize cell function and broaden the scope of regenerative therapies offered by Creative Medical. With a strong financial foundation - InvestingPro data shows the company holds more cash than debt and maintains a healthy current ratio of 19.13 - the firm appears well-positioned to pursue these developments.

One of the critical goals of this initiative is to reduce the need for immunosuppression in stem cell-based therapies, which can have severe side effects. By refining hypoimmune iPSC lines with AI assistance, the company seeks to develop safer and more effective treatments for diabetes and other chronic conditions.

Timothy Warbington, President and CEO of Creative Medical, expressed the company’s commitment to regenerative medicine and the potential impact of integrating AI into its development process. The firm anticipates that this approach will halve research and development time and yield significant cost savings.

The next development phase will concentrate on creating multi-gene edited hypoimmune iPSCs designed to evade immune detection and enhance survival and therapeutic potential. This could lead to cell-based regenerative therapies that do not require immunosuppression, significantly improving patient outcomes.

Creative Medical Technology Holdings specializes in regenerative therapies for diabetes, autoimmune disorders, orthopedic, and neurological diseases. While the company maintains a Fair financial health score according to InvestingPro, analysts anticipate continued investment phase with no profitability expected this year. This press release contains forward-looking statements, and actual results may vary. The information is based on a press release statement.

In other recent news, Creative Medical Technology Holdings, Inc. disclosed that its stockholders have approved an increase in the number of authorized shares of common stock from 5 million to 25 million, as indicated in an 8-K filing. The company’s board of directors also authorized the withdrawal of certificates of designation for Series A and Series B Preferred Stock. These developments were ratified during a Special Meeting of Stockholders.

Furthermore, stockholders approved the full exercise of warrants to purchase a total of 837,104 shares of the company’s common stock. These warrants were previously issued in a private placement. The voting results showed strong support for the proposed amendments and the exercise of the Investor Warrants.

In addition, Creative Medical Technology Holdings successfully completed a safety review for its ADAPT clinical trial, as announced recently. The independent Data Safety Monitoring Board (DSMB) concluded that the trial may continue without modifications after reviewing safety data from the first five patients. This represents a significant step in the clinical development of the company’s novel therapeutic product, CELZ-201, aimed at treating chronic lower back pain associated with degenerative disc disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.